0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Articles   |    
The Diminished Pipeline for Medications to Treat Mental Health and Substance Use Disorders
Peggy L. O'Brien, Ph.D., J.D.; Cindy Parks Thomas, Ph.D.; Dominic Hodgkin, Ph.D.; Katharine R. Levit, B.A.; Tami L. Mark, Ph.D., M.B.A.
Psychiatric Services 2014; doi: 10.1176/appi.ps.201400044
View Author and Article Information

Dr. O'Brien and Dr. Hodgkin are with the Institute for Behavioral Health and Dr. Thomas is with the Schneider Institute for Health Policy, Heller School of Social Policy and Management, Brandeis University, Waltham, Massachusetts (e-mail: pegmlob@brandeis.edu). Ms. Levit and Dr. Mark are with the Department of Behavioral Health and Quality Research, Truven Health Analytics, Washington, D.C.

Copyright © 2014 by the American Psychiatric Association

Abstract

Objective  Psychotropic drug development is perceived to be lagging behind other pharmaceutical development, even though there is a need for more effective psychotropic medications. This study examined the state of the current psychotropic drug pipeline and potential barriers to psychotropic drug development.

Methods  The authors scanned the recent academic and “grey” literature to evaluate psychotropic drug development and to identify experts in the fields of psychiatry and substance use disorder treatment and psychotropic drug development. On the basis of that preliminary research, the authors interviewed six experts and analyzed drugs being studied for treatment of major psychiatric disorders in phase III clinical trials.

Results  Interviews and review of clinical trials of drugs in phase III of development confirmed that the psychotropic pipeline is slim and that a majority of the drugs in phase III trials are not very innovative. Among the barriers to development are incentives that encourage firms to focus on incremental innovation rather than take risks on radically new approaches. Other barriers include human brain complexity, failure of animal trials to translate well to human trials, and a drug approval threshold that is perceived as so high that it discourages development.

Conclusions  Drivers of innovation in psychotropic drug development largely parallel those for other drugs, yet crucial distinctions have led to slowing psychotropic development after a period of innovation and growth. Various factors have acted to dry up the pipeline for psychotropic drugs, with expert opinion suggesting that in the near term, this trend is likely to continue.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
Table 1Status of drugs in open or active phase III drug trials for treatment of psychiatric disorders
Table Footer Note

a Some trials were listed in the clinical trials Web site under multiple disorders, such as comorbid alcohol use disorders and PTSD, which is considered an anxiety disorder.

Table Footer Note

b Includes drugs that were studied in combination

Table Footer Note

c Includes drugs that had not yet been approved by the U.S. Food and Drug Administration for any purpose, excluding drugs that are marketed as supplements

+

References

Blanco  C;  Xu  Y;  Brady  K  et al:  Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National Epidemiological Survey on Alcohol and Related Conditions.  Drug and Alcohol Dependence 132:630–638, 2013
[CrossRef] | [PubMed]
 
Kessler  RC;  Chiu  WT;  Demler  O  et al:  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.  Archives of General Psychiatry 62:617–627, 2005
[CrossRef] | [PubMed]
 
The Numbers Count: Mental Disorders in America. Rockville, Md, National Institute of Mental Health. Available at www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america/index.shtml#Intro. Accessed May 26, 2013
 
Pastor  PN;  Reuben  CA:  Diagnosed Attention Deficit Hyperactivity Disorder and Learning Disability: United States, 2004–2006 .  Hyattsville, Md,  Centers for Disease Control and Prevention, National Center for Health Statistics, 2008
 
Insel  TR:  Assessing the economic costs of serious mental illness.  American Journal of Psychiatry 165:663–665, 2008
[CrossRef] | [PubMed]
 
Miller TR, Hendrie D: Substance Abuse Prevention Dollars and Cents: A Cost-Benefit Analysis. DHHS pub no (SMA) 07-4298. Rockville, Md, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, 2008
 
Harwood  HJ:  Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data .  Bethesda, Md,  National Institute on Alcohol Abuse and Alcoholism, 2000
 
Harwood  HJ;  Bouchery  E:  The Economic Costs of Drug Abuse in the United States, 1992–1998 .  Washington, DC,  Office of National Drug Control Policy, 2004
 
Murrough  JW;  Charney  DS:  Is there anything really novel on the antidepressant horizon? Current Psychiatry Reports 14:643–649, 2012
[CrossRef] | [PubMed]
 
Ibrahim  HM;  Tamminga  CA:  Treating impaired cognition in schizophrenia.  Current Pharmaceutical Biotechnology 13:1587–1594, 2012
[CrossRef] | [PubMed]
 
Miyamoto  S;  Miyake  N;  Jarskog  LF  et al:  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.  Molecular Psychiatry 17:1206–1227, 2012
[CrossRef] | [PubMed]
 
Moghaddam  B;  Javitt  D:  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.  Neuropsychopharmacology 37:4–15, 2012
[CrossRef] | [PubMed]
 
Adams  CP;  Brantner  VV:  Spending on new drug development.  Health Economics 19:130–141, 2010
[CrossRef] | [PubMed]
 
Lesney  MS:  What about the FDA? Modern Drug Discovery 3:29–33, 2000. Available at pubs.acs.org/subscribe/archive/mdd/v03/i08/html/10clinical.html
 
The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. Silver Spring, Md, US Food and Drug Administration, 2013. Available at www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm. Accessed May 31, 2013
 
Medicines in Development: Mental Illness. Washington, DC, Pharmaceutical Research and Manufacturers of America, 2012. Available at www.phrma.org/sites/default/files/pdf/phrmamedsindevmentalillness2012.pdf
 
Vernon  JA;  Golec  JH;  Dimasi  JA:  Drug development costs when financial risk is measured using the Fama-French three-factor model.  Health Economics 19:1002–1005, 2010
[CrossRef] | [PubMed]
 
Frequently Asked Questions on Patents and Exclusivity. Silver Spring, Md, US Food and Drug Administration. Available at www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed Dec 5, 2012
 
Small Business Assistance: Frequently Asked Questions for New Drug Product Exclusivity. Silver Spring, Md, US Food and Drug Administration. Available at www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm069962.htm. Accessed May 31, 2013
 
Aitken ML, Berndt ER, Bosworth B, et al: The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity. NBER working paper 19487. Cambridge, Mass, National Bureau of Economic Research, 2013. Available at www.nber.org/papers/w19487.pdf
 
Hemphill  CS;  Sampat  BN:  Evergreening, patent challenges, and effective market life in pharmaceuticals.  Journal of Health Economics 31:327–339, 2012
[CrossRef] | [PubMed]
 
Thomas JR: Pharmaceutical Patent Litigation Settlements: Implications for Competition and Innovation. US Congressional Research Service, Jan 6, 2010. Available at scholarship.law.georgetown.edu/facpub/574
 
Kesselheim  AS;  Avorn  J:  Biomedical patents and the public’s health: is there a role for eminent domain? JAMA 295:434–437, 2006
[CrossRef] | [PubMed]
 
The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients. Washington, DC, Pharmaceutical Research and Manufacturers of America, 2013. Available at www.phrma.org/sites/default/files/pdf/phrmapipelinereportfinal11713.pdf
 
Hyman SE: Revolution stalled. Science Translational Medicine, 2012 (doi 10.1126/scitranslmed.3003142)
 
Insel TR: Next-generation treatments for mental disorders. Science Translational Medicine, 2012 (doi 10.1126/scitranslmed.3004873)
 
Sanders  L:  No new meds.  Science News 183:26–29, 2013
[CrossRef]
 
Friedman RA: A dry pipeline for psychiatric drugs. New York Times, Aug 19, 2013
 
Berk  M:  Pathways to new drug discovery in neuropsychiatry.  BMC Medicine 10:151, 2012
[CrossRef] | [PubMed]
 
Li  X;  Frye  MA;  Shelton  RC:  Review of pharmacological treatment in mood disorders and future directions for drug development.  Neuropsychopharmacology 37:77–101, 2012
[CrossRef] | [PubMed]
 
Philip NS, Carpenter LL, Tyrka AR, et al: The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal, 2012 (doi 10.1100/2012/104105)
 
Goff  DC;  Hill  M;  Barch  D:  The treatment of cognitive impairment in schizophrenia.  Pharmacology, Biochemistry, and Behavior 99:245–253, 2011
[CrossRef] | [PubMed]
 
Kantrowitz  J;  Javitt  DC:  Glutamatergic transmission in schizophrenia: from basic research to clinical practice.  Current Opinion in Psychiatry 25:96–102, 2012
[PubMed]
 
Huskamp  HA;  Busch  AB;  Domino  ME  et al:  Antidepressant reformulations: who uses them, and what are the benefits? Health Affairs 28:734–745, 2009
[CrossRef] | [PubMed]
 
Overview. Bethesda, Md, National Institute of Mental Health, Division of Adult Translational Research and Treatment Development. Available at www.nimh.nih.gov/about/organization/datr/index.shtml. Accessed Dec 10, 2013
 
Rorick-Kehn  LM;  Johnson  BG;  Knitowski  KM  et al:  In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.  Psychopharmacology 193:121–136, 2007
[CrossRef] | [PubMed]
 
Litten  RZ;  Egli  M;  Heilig  M  et al:  Medications development to treat alcohol dependence: a vision for the next decade.  Addiction Biology 17:513–527, 2012
[CrossRef] | [PubMed]
 
Vaughn P: NIH funding boosts new Alzheimer's research on prevention, novel drug targets. Bethesda, Md, National Institute on Aging, Sept 18, 2013. Available at www.nia.nih.gov/newsroom/2013/09/nih-funding-boosts-new-alzheimers-research-prevention-novel-drug-targets#.UlQXpxAqOxg
 
Cancer Research Funding. Bethesda, Md, National Cancer Institute. Available at www.cancer.gov/cancertopics/factsheet/NCI/research-funding. Accessed July 21, 2014
 
NAID's List of Foundations and Other Funding Sources. Bethesda, Md, National Institute of Allergy and Infectious Diseases. Available at www.niaid.nih.gov/researchfunding/ann/pages/found.aspx#Gates. Accessed July 21, 2014
 
Berndt  ER;  Cockburn  IM;  Grépin  KA:  The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications.  PharmacoEconomics 24(suppl 2):69–86, 2006
[CrossRef] | [PubMed]
 
Health, United States, 2011, With Special Feature on Socioeconomic Status and Health. DHHS pub no 2012-1232. Hyattsville, Md, National Center for Health Statistics, 2012
 
Rattinger  GB;  Burcu  M;  Dutcher  SK  et al:  Pharmacotherapeutic management of dementia across settings of care.  Journal of the American Geriatrics Society 61:723–733, 2013
[CrossRef] | [PubMed]
 
Vincent  GK;  Velkoff  VA:  The Next Four Decades: The Older Population in the United States: 2010 to 2050 .  Washington, DC,  US Census Bureau, 2010
 
Comer  JS;  Olfson  M;  Mojtabai  R:  National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007.  Journal of the American Academy of Child and Adolescent Psychiatry 49:1001–1010, 2010
[CrossRef] | [PubMed]
 
Merikangas  KR;  He  JP;  Rapoport  J  et al:  Medication use in US youth with mental disorders.  JAMA Pediatrics 167:141–148, 2013
[CrossRef] | [PubMed]
 
Olfson  M;  He  JP;  Merikangas  KR:  Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey–Adolescent Supplement.  Journal of the American Academy of Child and Adolescent Psychiatry 52:378–388, 2013
[CrossRef] | [PubMed]
 
Collins  SR;  Robertson  R;  Garber  T  et al:  Insuring the Future: Current Trends in Health Coverage and the Effects of Implementing the Affordable Care Act.  New York ,    Commonwealth Fund, 2013
 
Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. Silver Spring, Md, US Food and Drug Administration. Available at www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm. Accessed July 21, 2014
 
Albright B: Three key antipsychotics lose patent protection. Behavioral Healthcare, Nov 16, 2011. Available at www.behavioral.net/article/three-key-antipsychotics-lose-patent-protection
 
Davis  JC;  Furstenthal  L;  Desai  AA  et al:  The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise.  Nature Reviews Drug Discovery 8:279–286, 2009
[CrossRef] | [PubMed]
 
Harrison  PJ: The current and potential impact of genetics and genomics on neuropsychopharmacology. European Neuropsychopharmacology (Epub ahead of print, March 25, 2013). Available at www.europeanneuropsychopharmacology.com/article/S0924-977X(13)00071-0/abstract
 
Institute of Medicine:  Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis.    Washington, DC,  National Academies Press, 2013
 
D'Souza  DC;  Radhakrishnan  R;  Perry  E  et al:  Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.  Neuropsychopharmacology 38:492–503, 2013
[CrossRef] | [PubMed]
 
Morel  CM;  Mossialos  E:  Stoking the antibiotic pipeline.  BMJ 340:c2115, 2010
[CrossRef] | [PubMed]
 
Hecht  R;  Wilson  P;  Palriwala  A:  Improving health R&D financing for developing countries: a menu of innovative policy options.  Health Affairs 28:974–985, 2009
[CrossRef] | [PubMed]
 
Honig  PK:  Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology.  Clinical Pharmacology and Therapeutics 89:151–156, 2011
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 33.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 33.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 22.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 38.  >
APA Practice Guidelines > Chapter 13.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles